Concert Announces Clinical Advisory Board, New Medical Policies
Concert Announces Clinical Advisory Board, New Medical Policies
Drs. Beth Harris, Thomas Holland, Girish Putcha, and Michele Schoonmaker join board to advise Concert on clinical policy content
貝絲·哈里斯博士、托馬斯·霍蘭德博士、吉里什·普查博士和米歇爾·舒恩馬克博士加入董事會，就臨床政策內容向Concert提供建議
NASHVILLE, Tenn., May 1, 2024 /PRNewswire/ -- As part of its commitment to provide transparent, evidence-based medical policy and enable accurate reimbursement for a broader set of diagnostic services, Concert today announced the establishment of an advisory board of experts in clinical laboratory medicine and the release of policies for an expanded scope of routine and advanced laboratory testing.
田納西州納什維爾，2024年5月1日 /PRNewswire/ — 作爲提供透明、循證醫療政策併爲更廣泛的診斷服務提供準確報銷的承諾的一部分，Concert今天宣佈成立臨床實驗室醫學專家顧問委員會，併發布擴大常規和高級實驗室測試範圍的政策。
The newly formed board will advise Concert on its clinical laboratory content. Members include Drs. Beth Harris, Thomas Holland, Girish Putcha, and Michele Schoonmaker. Details on each board member appear below.
新成立的董事會將就其臨床實驗室內容向Concert提供建議。成員包括貝絲·哈里斯博士、托馬斯·霍蘭德博士、吉里什·普查博士和米歇爾·舒恩馬克博士。每位董事會成員的詳細信息如下所示。
"Expanding the expertise that informs our content means Concert can bring transparency and efficiency to a broader set of health services, while keeping our solutions tightly linked to the latest evidence and guidelines," said Gillian Hooker, Concert's Chief Scientific Officer. "We are thrilled Drs. Harris, Holland, Putcha, and Schoonmaker have decided to join us in this effort."
Concert首席科學官吉莉安·胡克說：“擴大爲我們的內容提供信息的專業知識意味着Concert可以爲更廣泛的醫療服務帶來透明度和效率，同時使我們的解決方案與最新的證據和指南緊密相連。”“我們很高興哈里斯博士、霍蘭德博士、Putcha博士和Schoonmaker博士決定加入我們的行列。”
In a separate release, Concert announced the expansion of the Diagnostic Benefit Program, formerly known as the Genetics Benefit Program, which now provides policies and payment accuracy capabilities across routine and advanced laboratory testing, enabling health plans to provide their members with access to these important clinical services at lower total costs, the company announced today.
該公司今天宣佈，在另一份新聞稿中，Concert宣佈擴大診斷福利計劃，前身爲遺傳學福利計劃，該計劃現在爲常規和高級實驗室測試提供政策和付款準確性，使健康計劃能夠以較低的總成本爲其成員提供獲得這些重要臨床服務的機會。
"Concert is working to align payers, providers, and labs to enable patient access to evidence-based testing," said Dr. Girish Putcha. "They have a comprehensive view of the industry so they can create transparent, scalable, and holistic solutions to structural problems in coding, coverage, and reimbursement that hinder precision medicine. I am excited to join this board to guide and support that work."
吉里什·普查博士說：“Concert正在努力協調付款人、提供商和實驗室，以使患者能夠獲得循證檢測。”“他們對行業有全面的了解，因此他們可以爲阻礙精準醫療的編碼、承保範圍和報銷方面的結構性問題創建透明、可擴展和全面的解決方案。我很高興加入這個董事會，爲這項工作提供指導和支持。”
Following are brief bios on each member of the new clinical advisory board, in alphabetical order by last name. More information can be found at Concert's new website at . With today's announcement, Concert Genetics will now operate by its abbreviated name, Concert, which many customers and partners have used for years to refer to the company.
以下是新臨床顧問委員會每位成員的簡要簡介，按姓氏的字母順序排列。更多信息可以在Concert的新網站上找到 。隨着今天的宣佈，Concert Genetics現在將使用其縮寫名稱Concert運營，許多客戶和合作夥伴多年來一直使用該縮寫名稱來指代該公司。
Beth Harris, MD
Dr. Harris is a gastrointestinal/hepatobiliary pathologist with extensive experience in both clinical practice and managed care. She served as a Medical Director at Humana and practiced as a gastrointestinal/hepatobiliary and surgical pathologist for PathGroup in Nashville, Tenn., and Associated Pathologists of Albuquerque in New Mexico. Today, she is a practicing pathologist at Covenant Physician Partners and an Assistant Professor of Pathology, Microbiology and Immunology at Vanderbilt University Medical Center. Dr. Harris completed her Bachelor of Science in Molecular Biophysics and Biochemistry at Yale University and her MD at University of Maryland School of Medicine. She completed her residency in anatomic pathology at Emory School of Medicine, and her fellowship in gastrointestinal/hepatobiliary at Vanderbilt.
貝絲哈里斯，醫學博士
哈里斯博士是一位胃腸道/肝膽病理學家，在臨床實踐和管理式護理方面擁有豐富的經驗。她曾在Humana擔任醫學董事，並在田納西州納什維爾的PathGroup和新墨西哥州阿爾伯克基的聯合病理學家擔任胃腸道/肝膽和外科病理學家。如今，她是盟約醫師合夥公司的執業病理學家，也是範德比爾特大學醫學中心的病理學、微生物學和免疫學助理教授。哈里斯博士在耶魯大學獲得分子生物物理學和生物化學理學學士學位，並在馬里蘭大學醫學院獲得醫學博士學位。她在埃默裏醫學院完成了解剖病理學實習，並在範德比爾特完成了胃腸道/肝膽學的獎學金。
Thomas Holland, MD, MSc-GH
Dr. Holland is an Associate Professor of Medicine, Division of Infectious Diseases, at Duke University, where he practices both as a hospitalist and infectious disease specialist. He has expertise in conducting multidisciplinary research in antimicrobial resistance, particularly in the design and conduct of clinical trials in Staphylococcus aureus infections. He additionally led the clinical response to the COVID pandemic at Duke Health, where he directed dedicated COVID wards, cared for patients, kept clinical teams up-to-date on rapidly evolving scientific and treatment information, and conducted clinical trials. He was awarded the Presidential Award for his efforts. A physician scientist with a deep interest in global health, Dr. Holland's work overseas has included investigating the prevalence of rheumatic heart disease in Kenya and working with a primarily Aboriginal population in the Australian Outback. Dr. Holland received his undergraduate degree from Princeton University in Ecology & Evolutionary Biology and his MD from Wake Forest University. He completed Internal Medicine residency and Infectious Diseases fellowship training at Duke, where he currently practices.
托馬斯·霍蘭德，醫學博士，理學碩士-GH
霍蘭德博士是杜克大學傳染病系醫學副教授，他在該校既是住院醫生，又是傳染病專家。他在開展抗微生物藥物耐藥性多學科研究方面擁有專業知識，特別是在設計和開展金黃色葡萄球菌感染臨床試驗方面。他還領導了杜克健康集團對COVID大流行的臨床應對，在那裏他指導了專門的COVID病房，爲患者提供護理，讓臨床團隊了解快速變化的科學和治療信息，並進行了臨床試驗。由於他的努力，他被授予總統獎。霍蘭德博士是一位對全球健康有着濃厚興趣的醫生科學家，他在海外的工作包括調查肯尼亞風溼性心臟病的患病率，以及與澳大利亞內陸地區以原住民爲主的人群合作。霍蘭德博士擁有普林斯頓大學生態與進化生物學本科學位和維克森林大學醫學博士學位。他在杜克大學完成了內科住院醫師和傳染病研究金培訓，目前他在杜克大學執業。
Girish Putcha, MD, PhD
Dr. Putcha is a molecular pathologist with extensive experience in academia, industry, the investment community, and payer coverage and reimbursement for molecular diagnostic tests. Recent roles include Director of Laboratory Science at Palmetto's MolDX program, Chief Medical Officer and Clinical Laboratory Director of Freenome, and Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) member. Today, he is an independent advisor at Precision Medicine & Diagnostics LLC. Dr. Putcha earned his undergraduate degree in biochemistry, medical ethics, and health policy from Rice University and his MD/PhD in neuroscience from Washington University in St. Louis. He completed his residency in clinical pathology and fellowship in molecular genetic pathology at Stanford University School of Medicine, where he also served as adjunct faculty.
Girish Putcha，醫學博士
Putcha博士是一位分子病理學家，在學術界、工業界、投資界以及分子診斷測試的付款人承保和報銷方面擁有豐富的經驗。最近的職位包括Palmetto的MoldX項目的實驗室科學主任、Freenome的首席醫學官兼臨床實驗室主任以及醫療保險證據開發與覆蓋諮詢委員會（MEDCAC）成員。如今，他是精準醫療與診斷有限責任公司的獨立顧問。Putcha 博士擁有萊斯大學生物化學、醫學倫理學和衛生政策學士學位以及聖路易斯華盛頓大學神經科學博士學位。他在斯坦福大學醫學院完成了臨床病理學住院醫師和分子遺傳病理學獎學金，並在那裏擔任兼職教師。
Michele Schoonmaker, PhD
Dr. Schoonmaker is a recognized expert in public policy and government affairs in the laboratory market. She spent 17 years with Cepheid, a leading molecular diagnostics company, where her primary responsibilities were to develop and implement global strategic reimbursement plans for Cepheid's molecular diagnostic product. Prior, Dr. Schoonmaker worked for the U.S. Food and Drug Administration (FDA) as a regulatory policy analyst and reviewer of diagnostic tests, and she was a Specialist in Genetics for the Congressional Research Service (CRS), a division of the Library of Congress. Dr. Schoonmaker earned her undergraduate degree in molecular biology from Goucher College and her PhD in health services research, genetics and public policy from Johns Hopkins University School of Hygiene and Public Health.
米歇爾·舒恩梅克博士
Schoonmaker博士是實驗室市場公認的公共政策和政府事務專家。她在領先的分子診斷公司Cepheid工作了17年，她的主要職責是爲Cepheid的分子診斷產品制定和實施全球戰略報銷計劃。此前，Schoonmaker博士曾在美國食品藥品監督管理局（FDA）擔任監管政策分析師和診斷測試審查員，並且是國會圖書館下屬國會研究局（CRS）的遺傳學專家。Schoonmaker 博士在古徹學院獲得分子生物學本科學位，在約翰·霍普金斯大學衛生與公共衛生學院獲得衛生服務研究、遺傳學和公共政策博士學位。
About Concert
Concert is a healthcare technology company enabling cost-effective access to diagnostics and therapeutics by harmonizing evidence, policy, and payment. Founded in 2010 to bring transparency and efficiency to genetic testing, Concert now offers the definitive precision health payment accuracy platform. The company combines proprietary market data, clinical and coding expertise, and patented technology to support diagnostic test ordering, resulting, coding, coverage, claim editing, and payment integrity. Concert Genetics, now operates by its abbreviated name, Concert. For more information, visit .
關於音樂會
Concert 是一家醫療保健技術公司，通過協調證據、政策和付款，提供具有成本效益的診斷和治療方法。Concert成立於2010年，旨在提高基因檢測的透明度和效率，現在提供權威的精準醫療支付準確性平台。該公司結合了專有的市場數據、臨床和編碼專業知識以及專利技術，以支持診斷測試的訂購、結果、編碼、承保範圍、索賠編輯和支付完整性。Concert Genetics現在以其縮寫名稱Concert運營。欲了解更多信息，請訪問。
Contact: Nick Tazik, [email protected]
聯繫人：尼克·塔齊克，[email protected]
SOURCE Concert
來源 Concert
譯文內容由第三人軟體翻譯。